Yamashita Nobuyuki, Tanimoto Hironori, Shimoda Shinji, Komori Atsumasa, Nomura Hideyuki
The Center for Liver Disease, Shin-Kokura Hospital, 1-3-1 Kanada, Kokurakitaku, Kitakyushu, Fukuoka, 803-8505, Japan.
Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Clin J Gastroenterol. 2018 Dec;11(6):497-500. doi: 10.1007/s12328-018-0876-y. Epub 2018 Jun 11.
We herein report the case of a woman in her 80s with a recurrent hepatocellular carcinoma (HCC) tumor that rapidly increased in size during direct-acting antiviral (DAA) treatment. She suffered from HCC at her initial visit to our department and underwent hepatectomy. Thereafter, she underwent DAA treatment for chronic hepatitis C; however, her alpha-fetoprotein (AFP) level rapidly increased, and a liver tumor of > 1 cm in diameter was observed that had not been seen immediately before DAA treatment. She underwent hepatectomy again and moderate to poorly differentiated HCC was diagnosed. The patient's AFP level showed a rapid increase immediately after the start of DAA treatment; however, the increase ceased after the first month, and the influence from the surrounding environment of the tumor was considered to be temporary.
我们在此报告一例80多岁女性复发性肝细胞癌（HCC）的病例，该肿瘤在直接抗病毒药物（DAA）治疗期间迅速增大。她初次就诊于我院时被诊断为HCC，并接受了肝切除术。此后，她接受了DAA治疗慢性丙型肝炎；然而，她的甲胎蛋白（AFP）水平迅速升高，并且观察到直径>1厘米的肝肿瘤，而在DAA治疗前并未立即发现该肿瘤。她再次接受了肝切除术，病理诊断为中分化至低分化HCC。患者的AFP水平在DAA治疗开始后立即迅速升高；然而，在第一个月后升高停止，认为肿瘤周围环境的影响是暂时的。
